title: NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
authors.affiliation: Department of Dermatology and Academic Wound Healing, Division of Infection & Immunity, Cardiff University, Cardiff, U.K.
authors.forename: J R
authors.identifier: 0000-0002-5257-1142
authors.initials: JR
authors.lastname: Ingram
authors.affiliation: HS Trust, Cliffe House, St Anthonys Way, Rochester, U.K.
authors.forename: T
authors.initials: T
authors.lastname: Burton
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000068879:Adalimumab